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Abstract
Purpose CARD15 mutations are associated with higher
susceptibility to Crohn's disease (CD) and longstanding
colonic CD increases the risk of developing colorectal
cancer (CRC). The relation between these mutations and
sporadic CRC remains controversial. The aim of this study
was to assess whether germline and/or somatic CARD15
mutations are risk factors for sporadic CRC in Portugal
and whether there are genotype–phenotype correlations in
these patients.
Methods The three main CARD15 mutations (R702W,
G908R and 3020insC) were researched in 112 sporadic
CRC patients and 152 healthy subjects.
Results Overall, CARD15 mutations were found in 18
patients (16.1%) and in 15 controls (9.9%; p=0.132).
Individually, the incidence of R702W was significantly
higher in patients than in controls (12.5% vs. 5.3%, p=
0.035), whereas the genotype frequencies for G908R
(2.7% vs. 3.3%) and 3020insC (0.9% vs. 1.3%) were not
statistically different between the two groups. Entire
genotypic agreement was found in patients genotyped for
blood and neoplastic DNA. A significantly higher inci-
dence of CARD15 mutations was detected in patients with
CRC diagnosed under 60 years old (28.6% vs. 10.4%, p=
0.015) and in female patients (24.4% vs. 10.4%, p=
0.048). No associations were found between CARD15
mutations and family history, symptoms or CRC patho-
logic characteristics.
Conclusions The CARD15 R702W variant might be a
predisposing factor to sporadic CRC in Portugal, particu-
larly in patients under 60-years old and in female patients.
This susceptibility appears to be linked with germline
CARD15 mutations. Nevertheless, we have found no
evidence that CARD15 mutations predict the pathologic
characteristics of CRC.
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Introduction
In developed countries, colorectal cancer (CRC) is one of the
most frequent malignancies and is the second most common
cause of malignant deaths, preceded only by lung cancer [1, 2].
The incidence of CRC in Portugal was 77 new cases per
100,000 inhabitants in 2006, one of the highest in the Western
world [3].
Germline mutations in tumour-suppressor adenomatous
polyposis coli genes and DNA mismatch repair genes lead
to the recognised familial adenomatous polyposis related
CRC and hereditary non-polyposis CRC, respectively [4].
These inherited cases account for about 5–10% of CRC
[4]. Excluding inherited types of CRC, the susceptibility
of a particular individual to developing sporadic CRC
remains largely undetermined. Nevertheless, the patho-
genesis of sporadic CRC is thought to be multifactorial,
involving multiple genetic and various environmental
factors [5–7].
Bacterial flora keeps the normal colon mucosa in a
continuous state of low-grade inflammation, stimulating the
release of various pro-inflammatory cytokines by the immune
cells [8]. Several epidemiological and biological data support
a clear association between chronic inflammation and cancer
[9]. Typical examples are the causal connection between
Helicobacter pylori-induced chronic gastritis and the devel-
opment of mucosal-associated lymphoid tissue (MALT) B
cell lymphoma and/or gastric cancer [10], as well as the
association between longstanding inflammatory bowel dis-
ease (IBD) and CRC [11]. In fact, it is estimated that up to
15% of all IBD patients will develop CRC [11]. Further-
more, precursor CRC lesions may often have inflammatory
histological features [8, 12] and pro-inflammatory genes
have been shown to be important in the maintenance and
progression of CRC [13]. In addition, inflammation may
favour tumourigenesis by inducing DNA damage [14, 15],
stimulating continuous cell proliferation [16, 17] and
arousing angiogenesis [18]. Finally, regular use of nonste-
roidal anti-inflammatory drugs, such as aspirin, exhibits
chemoprevention effect of CRC [19].
How the increased risk of CRC in IBD patients is mediated
remains undefined. Nevertheless it is thought to involve genes
linked to the inflammatory response, which result in the
activation of neutrophils and the consequent generation of
significant amounts of reactive oxygen species [20]. The
continuous exposure of the gastrointestinal epithelium to
reactive oxygen species is believed to be associated with an
amplified mutation rate, which results in an increased
likelihood of tumour development [20]. Thus, assuming that
the underlying chronic inflammation in IBD is involved in
the progression of CRC, genetic factors implicated in the
chronic inflammatory process of IBD may simultaneously
predispose patients without IBD to CRC.
There is strong evidence that CARD15 mutations increase
susceptibility to Crohn's disease (CD) [21–25]. Hence, the
possible association of CARD15 mutations with sporadic
CRC has been studied recently in Polish, Greek, Finnish, New
Zealand, Hungarian and German Caucasian CRC patients, but
the results have been controversial (Table 1) [26–32].
Furthermore, almost all of these studies only assessed
CARD15 mutations in DNA extracted from blood or non-
neoplastic tissue, i.e. involving only research of germline
mutations [26, 27, 29–32]. Clarifying the potential involve-
ment of CARD15 somatic mutations in the pathogenesis of
CRC also requires investigation in the neoplastic tissue.
Therefore, at this stage, the role of CARD15 variants in the
development of CRC remains unclear. In light of these
findings, and given that the frequency of CARD15 mutations
varies in different populations, our aim was to investigate
whether germline and/or somatic CARD15 mutations in-
creased susceptibility to sporadic CRC in Portugal, a country
with a high incidence and mortality associated with this
disease. Additionally, we intended to investigate whether there
are genotype–phenotype correlations in these patients.
Methods
Patients
One hundred and twelve consecutive Portuguese patients with
CRC and without a previous diagnosis of IBD or any of the
known hereditary cancer syndromes (male/female: 67/45;
mean age at diagnosis of CRC 64.3±9.9 years old) and 152
healthy (cancer-free blood donors) sex-matched controls,
drawn from the central region of Portugal, were genotyped
for the three main CARD15 mutations. Genomic DNA was
isolated from whole blood in all the study participants and in
14 CRC patients it was also isolated from neoplastic biopsy
specimens.
The vast majority of the group studied consisted of truly
sporadic cases (95 patients, 84.8%), whilst 17 patients (15.2%)
reported a history of CRC in at least one first-degree relative.
Comprehensive clinical data, including age and symptoms
at diagnosis and the clinicopathologic characteristics of the
tumour, were collected from each patient.
The research was approved by the local Ethics Committee
and informed consent was obtained from all participants prior
to enrolment into the study, in accordance with the Declaration
of Helsinki.
Sample DNA extraction and genotyping
Genomic DNA was isolated from whole blood and biopsy
specimens in accordance with the QIAamp Mini Kit
(QIAGEN GmbH, Germany).
1212 Int J Colorectal Dis (2010) 25:1211–1219
All participants were genotyped for the three major CARD15
mutations: R702W (SNP8), G908R (SNP12) and 3020insC
(SNP13). Genotyping was performed by real-time polymerase
chain reaction (PCR): variants R702W and G908R using
HybProbe (FRET) and 3020insC variant using SimpleProbe.
The R702W variant was amplified and detected using the
forward primer 5′-AgCCgCACAACCTTAgATCAC-3′, the
reverse primer 5′-gCgggCACAggCATAgC-3′, the anchor
probe 5′-LC Red640-gTCTggCACTCAgCCAgCAggCCCC-
PH and the donor probe 5′-gCgCCAgAgCAgggCCTTCTCA-
FL. For assay of the G908R mutation, 5′-gCACATATCAggTA
CTCACTgACACT-3′ was used as the forward primer, 5′-TTA
CCTgAgCCACCTCAAgC-3′ as the reverse primer, 5′-LC
Red705-CTgAAAAggCCAAAAgAgTCAACAgAC-PH as
the anchor probe and the 5′-CCACTCTgTTgCCCCAgAA-FL
as the donor probe. In order to detect the 3020insC variant,
PCR was carried out using the forward primer 5′-gACAgg
TgggCTTCAgTAgA-3′, the reverse primer 5′-TgAggTTCggA
gAgCTAAAACAg-3′ and the simple probe 5′-CTgCAggCCC
CTTgAAAg-FLQ.
The reaction mixture consisted of 18 μl of the PCR
master mix plus 2 μl of the DNA of each patient. The PCR
master mix for the R702W variant included 5.0 mM
MgCl2, 1× LightCycler DNA master hybridization probes
(Roche, Mannheim, Germany), 0.5 μM each primer and
0.1 μM each fluorescein and LC-Red-640-labelled probe.
Cycling parameters consisted of one cycle of 95°C for
2 min, followed by amplification for 45 cycles of 95°C for
0 s, 55°C for 10 s, and 72°C for 5 s. A melting curve was
created by measuring the fluorescent signal generated with
the following profile: 95°C for 5 s, 50°C for 10 s, and 90°C
for 0 s with a slope 0.4°C/s transition. The PCR master mix
for the G908R mutation included 2.5 mM MgCl2, 1×
LightCycler DNA master hybridization probes (Roche,
Mannheim, Germany), 0.5 μM each primer and 0.2 μM
each fluorescein and LC-Red-705-labelled probe. Cycling
parameters consisted of one cycle of 95°C for 2 min,
followed by amplification for 40 cycles of 95°C for 10 s,
57°C for 8 s, and 72°C for 17 s. A melting curve was
originated by measuring the fluorescent signal generated
Table 1 CARD15 and colorectal cancer: summary of association analyses
Country
[Reference]
Poland [26] Greece
[27]
Finnland
[28, 29]
New Zealand
[30]
Hungary
[31]
Germany [32]
≤50yearsa >50yearsa Total ≤50yearsa
CRC (n) 50 250 104 953/960/926c 133 194 1044 143
Controls (n) 300 300 100 508/508/348c 201 200 724 724
R702W
CRC % Allele
frequency
– – 4.8 2.2 7.1 1.8 5.1 7.7
Control % Allele
frequency
– – 1.0 2.1 3.0 1.5 4.6 4.6
p value – – 0.02 0.88 0.03 0.78 0.5 0.03
G908R
CRC % Allele
frequency
– – 8.65 0.3 2.2 1.8 1.5 2.1
Control % Allele
frequency
– – 3.5 0.2 0.8 1.8 1.2 1.2
p value – – 0.025 0.57 0.09 0.95 0.43 0.36
3020insC
CRC % Allele
frequency
2b 14.4b 12.5 1.9 2.2 3.6 3.6 3.8
Control % Allele
frequency
7b 7b 6 1.9 1.0 2.5 2.8 2.8
p value 0.3010 0.0046 0.017 0.96 0.19 0.40 0.17 0.32
R702W/G908R/3020insC
CRC % Genotype
frequency
– – 51.9 – 21.8 14.4 10.2 25.2
Control % Genotyple
frequency
– – 21.0 – 8.9 11.5 8.6 8.6
p value – – <0.0001 – 0.001 0.45 0.10 0.038
CRC colorectal cancer
a Age at diagnosis of CRC
b Genotype frequencies of carriership of mutant allele
c In the investigation of R702W, G908R and 3020insC were utilised 953, 960 and 926 CRC cases and 508, 508 and 348 controls, respectively
Int J Colorectal Dis (2010) 25:1211–1219 1213
with the following profile: 95°C for 20 s, 40°C for 20 s, and
85°C for 0 s with a slope 0.2°C/s transition. Finally, the
PCR master mix for the 3020insC variant included 2.5 mM
MgCl2, 1× LightCycler DNA master hybridization probes
(Roche, Mannheim, Germany), 0.2 μM forward primer,
0.5 μM reverse primer and 0.2 μM simple probe. Cycling
parameters consisted of 1 cycle of 95°C for 2 min,
followed by amplification for 40 cycles of 95°C for 10 s,
55°C for 10 s, and 72°C for 20 s. A melting curve was
created by measuring the fluorescent signal generated
with the following profile: 95°C for 20 s, 40°C for 20 s,
and 85°C for 0 s with a slope 0.2°C/s transition. Sterile
water was used as a negative control. The change of
fluorescence was converted to a melting peak (Tm) by
plotting the negative derivative of the fluorescent signal
corresponding to the temperature (−dF/dT) with the
LightCycler software.
The sequence variations of the PCR products were
confirmed by DNA sequencing.
Statistical analysis
The significance of the differences in CARD15 genotype
frequencies between CRC patients and controls, as well
as the association of CARD15 variants with the clinico-
pathologic characteristics, were assessed using χ2 tests.
Odds ratios (OR) were determined with the corresponding
χ2 distribution test and 95% confidence intervals (95%
CI).
Survival and recurrence cumulative curves as a function
of time were produced utilising the Kaplan–Meier approach
and compared with the log-rank test.
Only p values <0.05 were considered significant.
Each genetic variant studied was in Hardy–Weinberg
equilibrium.
The data was analysed using the Statistical Package for
Social Sciences-SPSS (SPSS Inc., Chicago, Illinois, USA)
computer software for Windows (version 17.0).
Results
The combined genotype frequency of R702W/G908R/
3020insC was not statistically different between CRC
patients and controls (16.1% vs. 9.9%, p=0.132; OR,
1.75; 95% CI, 0.84–3.64; Table 2). Individually, R702W
was significantly more frequent in the CRC patients than
the controls (12.5% vs. 5.3%, p=0.035; OR, 2.57; 95% CI,
1.04–6.36), whereas comparable genotypic frequencies of
G908R and 3020insC were observed in both groups
(Table 2). Among subjects with CARD15 mutations, only
one patient was homozygous for R702W, whilst all the
others were heterozygous for a particular mutation (Table 2).
No compound heterozygous carriers were identified.
In the 14 patients genotyped for CARD15 mutations with
DNA isolated from whole blood and also with DNA
isolated from neoplastic biopsy specimens, complete
genotypic agreement was found between the two samples,
namely two patients heterozygous for R702W and the
remaining 12 wild-type homozygous.
At least one variant of the CARD15 was detected in ten
(28.6%) of the 35 patients with CRC diagnosed under
60 years old and in eight (10.4%) of the 77 patients
with ≥60 years old at diagnosis of CRC (p=0.015; OR,
3.45; 95% CI, 1.22–9.72; Table 3). Female CRC patients
were more likely to carry a CARD15 mutation than their
male counterparts (24.4% vs. 10.4%, p=0.048; OR, 2.77;
95% CI, 0.98–7.82; Table 3). In contrast, patients having at
least one first-degree relative diagnosed with CRC were no
more likely to carry a CARD15 mutation than patients
Variant Genotype p OR (95% CI)
WT/WT WT/MUT MUT/MUT
R702W
CRC 98 13 1 0.035 2.57 (1.04–6.36)
Control 144 8 0
G908R
CRC 109 3 0 0.775 0.81 (0.19–3.46)
Control 147 5 0
3020insC
CRC 111 1 0 0.749 0.68 (0.06–7.55)
Control 150 2 0
R702W/G908R/3020insC
CRC 94 17 1 0.132 1.75 (0.84–3.64)
Control 137 15 0
Table 2 Genotype frequencies
of the CARD15 variants in CRC
patients and controls
p value and respective OR (odds
ratio) for differences in genotype
frequencies between patients
and controls
CRC colorectal cancer, WTwild-
type, MUT mutant, WT/WT ho-
mozygous wild-type, WT/MUT
heterozygous, MUT/MUT ho-
mozygous mutant, OR odds ra-
tio, CI confidence interval
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without this familial aggregation (11.8% vs. 16.8%,
respectively; p=0.600; OR, 0.66; 95% CI, 0.14–3.17).
No associations were found between carriers of CARD15
mutations and clinical manifestations, neither with tumour
stage, size, differentiation or location (Table 3). Similarly,
we did not find any correlation between CARD15 mutations
and survival or recurrence rates (Fig. 1).
In assessing genotype–phenotype correlations based
only on the presence or absence of the CARD15 R702W
variant, we detected a statistical significance for the same
correlations, namely a significantly higher incidence of
mutation in patients with CRC diagnosed under 60 years
old and in female patients (Table 4 and Fig. 2).
Discussion
IBD-related cancer serves as an excellent model of
inflammation-associated cancer and might also provide
many important clues to understanding the pathogenesis
of sporadic CRC [11]. Thus, because the normal colon is
arguably in a continual state of low-grade inflammation in
response to its microbial flora, it is reasonable to speculate
that, apart from IBD-associated CRC, sporadic CRC might
be consequence of bacteria-induced inflammation [8].
Polymorphisms in CARD15 have been associated with
increased susceptibility to IBD, particularly to CD [21–25].
This discovery has led researchers to investigate the
Table 3 Clinicopathologic features of CRC patients with and without CARD15 mutations
Variables Total n Carriersan (%) Non carriers n p OR (95% CI)
Gender
Female 45 11 (24.4) 34 0.048 2.77 (0.98–7.82)
Male 67 7 (10.4) 60
Age at diagnosisb
<60 years 35 10 (28.6) 25 0.015 3.45 (1.22–9.72)
≥60 years 77 8 (10.4) 69
Symptoms at diagnosisc
Yes 97 16 (16.5) 81 0.756 1.28 (0.26–6.25)
No 15 2 (13.3) 13
Tumour location
Rectum 52 8 (15.4) 44 0.854 (rectum vs. left+right) 0.91 (0.33–2.51)
Left-colon 29 6 (20.7) 23 0.572 (rectum+left vs. right) 1.41 (0.43–4.67)
Right-colon 31 4 (12.9) 27
Tumour size (mm)
<30 28 3 (10.7) 25 0.373 0.55 (0,15–2.07)
≥30 84 15 (17.9) 69
Differentiation
Good 84 14 (16.7) 70 0.766 (good vs. moderate+poor) 1.20 (0.36–4.00)
Moderate 24 4 (16.7) 20 0.373 (good+moderate vs. poor) –
Poor 4 0 (0) 4
T stage
1 16 3 (18.8) 13 0.753 (T1 vs. T2+T3+T4) 1.25 (0.32–4.91)
2 12 1 (8.3) 11 0.766 (T1+T2 vs. T3+T4) 0.83 (0.25–2.78)
3 66 12 (18.2) 54 0.532 (T1+T2+T3 vs. T4) 1.64 (0.34–7.85)
4 18 2 (11.1) 16
N stage
0 59 9 (15.2) 50 0.804 0.88 (0.32–2.41)
1 or 2 53 9 (17.0) 44
M stage
0 91 15 (16.5) 76 0.805 1.18 (0.31–4.53)
1 21 3 (14.3) 18
CRC colorectal cancer, OR odds ratio; CI confidence interval
a Patients with CARD15 R702W, G908R or 3020insC variants.
b Patients were divided into early (<60 years at diagnosis) and late (≥60 years at diagnosis) onset groups as in previous studies [27, 29–31], to allow for
comparison.
c Symptoms: hematochezia, weight loss, anaemia, changes in bowel movement habits.
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possible influence of this gene on the development of
sporadic CRC, but the studies in this area have led to
controversial results [26–32]. However, it has been dem-
onstrated that there is regional heterogeneity within Europe
in terms of the contribution of CARD15 variants to CD
susceptibility, reflecting the effects of differing founder
populations, and we can suppose that the same phenome-
non can be seen in CRC [21, 24, 25, 33–35]. Given this
data and knowing the high CRC incidence and mortality
rate in our country, this paper aimed to clarify whether
germline and/or somatic CARD15 mutations increase
susceptibility to sporadic CRC in the Portuguese population
and whether there are genotype–phenotype correlations in
these patients.
We found that the frequency of R702W was significantly
higher in the CRC patients than in the controls, whereas the
frequency of G908R and 3020insC and the combined
frequencies of the three key CARD15 mutations did not
differ significantly between the two groups. These results
agree with the findings of Roberts et al. in the New Zealand
population where, in assessing the effect of each variant
individually in a series of 133 CRC patients, only a
significant association between R702W and CRC was
detected (OR=2.30; 95% CI, 1.1–5.0) [30]. However, in
the New Zealand study, contrarily to our work, evidence for
the association of the combined frequency of the three
common CARD15 variants with the risk of CRC was
obtained (OR=2.8; 95% CI, 1.5–5.4) [30]. Moreover,
Papaconstantinou et al. [27] found that all the three major
CARD15 mutations were significantly elevated in Greek
CRC patients (OR=4.06; 95% CI, 2.19–7.52), in Poland
Kurzawski et al. [26] described an association between the
CARD15 3020insC variant and CRC in patients aged over
50 at the time of diagnosis (OR=2.23; 95% CI, 1.23–4.10)
and recently a study conducted by Möckelmann et al. [32]
found a significant association between CARD15 mutations
and CRC susceptibility in a German cohort of patients aged
under 50 (p=0.038). In contrast, Alhopuro et al. and
Tuupanen et al. found no link between CRC and any of the
three main CARD15 mutations in a population-based series
of 1042 Finnish CRC patients, although it must be borne in
mind that the background frequency of CARD15 variants in
the Scandinavian population is much lower [28, 29].
Likewise, Lakatos et al. observed similar variant allele
frequencies in both the patient and control Hungarian
groups [31].
As in CD, where CARD15 mutations are associated with
the early onset of disease, ileal localization and stricturing
phenotype, it is possible that these mutations may also be
predictive of the age of CRC presentation and of tumour
behaviour [36–41]. Associations between CARD15 variants
and specific clinicopathologic characteristics were observed
in the Polish, Greek, New Zealand and German CRC
cohorts [26, 27, 30, 32]. Within the Polish CRC cohort, the
frequency of the 3020insC variant was found to be
significantly elevated in patients aged over 50 at the time
of diagnosis [26]. In the Greek cohort, the CARD15 variant
carriers had more frequently advanced stage tumours [27].
Fig. 1 Cumulative survival and
recurrence rates in colorectal
cancer patients with and without
CARD15 mutations
Fig. 2 Cumulative survival and
recurrence rates in colorectal
cancer patients with and without
CARD15 R702W variant
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In the New Zealand study, female CRC patients were far
less likely to carry a CARD15 mutation than their male
counterparts [30]. Finally, in the German cohort, the
frequency of R702W and the combined frequency of
genotypes harbouring R702W, G908R or 3020insC were
found to be significantly higher in patients ≤50 years old
at the time of the CRC diagnosis [32]. In our CRC cohort
we found a significantly higher incidence of CARD15
mutations in patients diagnosed under 60 years old and in
female patients, and we did not detect any differences in
tumour behaviour between individuals who carried
CARD15 mutations and those who had a wild-type
CARD15 genotype. These data suggest that also with
regard to genotype–phenotype correlations there is regional
heterogeneity.
As in other studies, we found no association between
CARD15 mutations and a familial aggregation of CRC [26,
28, 29].
In order to assess the possible contribution of loss of the
wild-type CARD15 allele in 3020insC-related tumouri-
genesis, Alhopuro et al. sequenced the tumour tissue
DNA of all the patients heterozygous for the CARD15
3020insC variant in normal tissue DNA [28]. They found
loss of heterozygosity in only one of the 33 heterozygous
patients and concluded that there was no evidence of
contribution of loss of the wild-type CARD15 allele in the
Table 4 Clinicopathologic features of CRC patients with and without CARD15 R702W variant
Variables Total n Carriersa n (%) Noncarriers n p OR (95% CI)
Gender
Female 45 9 (20.0) 36 0.049 3.10 (0.96–9.97)
Male 67 5 (7.5) 62
Age at diagnosisb
<60 years 35 9 (25.7) 26 0.004 4.99 (1.53–16.25)
≥60 years 77 5 (6.5) 72
Symptoms at diagnosisc
Yes 97 12 (12.4) 85 0.916 0.92 (0.18–4.58)
No 15 2 (13.3) 13
Tumour location
Rectum 52 4 (7.7) 48 0.152 (rectum vs. left+right) 0.42 (0.12–1.42)
Left-colon 29 6 (20.7) 23 0.936 (rectum+left vs. right) 0.95 (0.28–3.29)
Right-colon 31 4 (12.9) 27
Tumour size (mm)
<30 28 2 (7.1) 26 0.322 0.46 (0.10–2.20)
≥30 84 12 (14.3) 72
Diferentiation
Good 84 11 (13.1) 73 0.741 (good vs. moderate+poor) 1.26 (0.32–4.87)
Moderate 24 3 (12.5) 21 0.441 (good+moderate vs. poor) –
Poor 4 0 (0) 4
T stage
1 16 1 (6.3) 15 0.414 (T1 vs. T2+T3+T4) 0.43 (0.05–3.50)
2 12 0 (0) 12 0.099 (T1+T2 vs. T3+T4) 0.20 (0.03–1,62)
3 66 11 (16.7) 55 0.846 (T1+T2+T3 vs. T4) 1.17 (0.24–5.74)
4 18 2 (11.1) 16
N stage
0 59 8 (13.6) 51 0.721 1.23 (0.40–3.81)
1 or 2 53 6 (11.3) 47
M stage
0 91 12 (13.2) 79 0.647 1.44 (0.30–7.00)
1 21 2 (9.5) 19
CRC colorectal cancer, OR odds ratio, CI confidence interval
a Patients with CARD15 R702W variant.
b Patients were divided into early (<60 years at diagnosis) and late (≥60 years at diagnosis) onset groups as in previous studies [27, 29–31], to allow for
comparison
c Symptoms: hematochezia, weight loss, anaemia, changes in bowel movement habits.
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CRC carcinogenesis [28]. These results do not allow any
conclusions to be drawn as to whether CARD15 somatic
mutations are involved in the predisposition to CRC. This
assessment also implies the genotyping of tumour tissue
DNA in patients without CARD15 mutations in non-
neoplastic DNA. In our work, the entire CARD15 genotypic
agreement between blood and neoplastic samples suggests
that CRC susceptibility associated with CARD15 variants is
linked to germline mutations without the apparent partici-
pation of somatic mutations. To our knowledge, this is the
only study involving research of CARD15 variants in both
neoplastic and non-neoplastic DNA within a random group
of CRC patients. Thus, it is also the first study suggesting
that only CARD15 germline mutations are involved in the
increased susceptibility to CRC associated with this gene.
This important and interesting topic needs further confir-
mation in different and larger samples of CRC patients.
The potential limitations of our study should be
mentioned. Firstly, the size of the study population is
relatively small. Secondly, as CARD15 is associated with
immune modulation, we cannot rule out the fact that other
genetic factors involved in the immune response or
implicated in the control of inflammatory response may
also contribute to the risk of disease. Thirdly, the potential
effect of environmental factors and/or their interaction with
CARD15 mutations have not been evaluated. Finally, this
work was performed in a teaching and referral hospital and
therefore our results may not be applicable to institutions
with different patient populations.
Our findings suggest that genetic variability within
CARD15 may be one of the factors contributing to the
elevated risk of CRC observed in the Western world, and
particularly in Portugal. However, the available results
show regional heterogeneity in terms of the contribution of
CARD15 variants to CRC susceptibility. Moreover, envi-
ronmental factors and additional genetic factors vary
greatly between populations, and genetic polymorphisms
are thought to play a role in determining how individuals
respond at cellular level to various environmental factors
[42]. Thus, further data from different and larger popula-
tions is needed to determine whether CARD15 mutations
lead to a predisposition to CRC and, if so, to identify the
additional determinants necessary for this increased sus-
ceptibility. A thorough investigation of these issues may
improve screening recommendations, could shed light on
the mechanisms of sporadic malignancy initiation and
progression and might be critical to the development of
pharmaceutical agents for cancer chemoprevention. Addi-
tionally, further research is needed in order to clarify the
potential role of CARD15 mutations in cancer pathogenesis
and pathophysiology.
In conclusion, our study suggests that the CARD15
R702W variant might be a predisposing factor to sporadic
CRC in the Portuguese population, particularly for those
aged under 60 and in female patients. Additionally, this is
the first study to hint that this susceptibility to CRC is
linked only to germline CARD15 mutations. Nevertheless,
CARD15 mutations do not appear to influence the patho-
logical expression of CRC in Portuguese patients. Regional
heterogeneity within the CARD15 genotype in CRC
patients shows the importance of the genetic assessment
and evaluation of its correlation with the phenotype in
different populations. Additional research, using larger
patient groups as well as other populations, is required in
order to unequivocally determine the role of CARD15
variants in CRC risk and carcinogenesis.
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